Are you Dr. Irizarry?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 64 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
15 Parkman St
Wac 830
Boston, MA 02114Phone+1 617-726-1728Fax+1 617-726-4101- Is this information wrong?
Summary
- Dr. Michael Irizarry, MD is a board certified neurologist in Boston, Massachusetts. He is currently licensed to practice medicine in North Carolina. He is a VP Early Clinical Development at Ltd..
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
Massachusetts General HospitalInternship, Internal Medicine, 1990 - 1991
Georgetown University School of MedicineClass of 1990
Certifications & Licensure
NC State Medical License 2006 - 2024- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 38 citationsNew directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.Adam L. Boxer, Michael Gold, Howard Feldman, Bradley F. Boeve, Susan Dickinson, Howard Fillit, Carole Ho, Robert H. Paul, Rodney Pearlman, Margaret Sutherland, Ajay Ve...> ;Alzheimer's & Dementia. 2020 Jan 1
- 38 citationsSecondary prevention of Alzheimer's dementia: neuroimaging contributionsMara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N.M. van Berckel, Michael Ewers, Chris Foley, Juan Domingo Gispert, Derek L. G. Hill, M...> ;Alzheimer's Research & Therapy. 2018 Oct 30
- 44 citationsTopographic staging of tau positron emission tomography images.Adam J. Schwarz, Sergey Shcherbinin, Lawrence J. Slieker, Shannon L. Risacher, Arnaud Charil, Michael C. Irizarry, Adam S. Fleisher, Sudeepti Southekal, Abhinay D. Jos...> ;Alzheimer's & Dementia. 2018 Jan 1
- Join now to see all
Press Mentions
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the ad/pd™ 2023 Annual MeetingMarch 22nd, 2023- FDA Approves, Leqembi, New Treatment for Early Alzheimer’sJanuary 6th, 2023
- Michael Irizarry, S.VP, Clinical Research,Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAICDecember 14th, 2022
- Join now to see all
Grant Support
- Transgenic Models Of Alzheimers DiseaseNational Institute On Aging1997–2001
